Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens

被引：13

作者：

Milano, Francesca ^{[1
]}

Krishnadath, Kausilia K. ^{[2
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands

[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands

来源：

HUMAN IMMUNOLOGY | 2008年 / 69卷 / 10期

关键词：

Esophageal adenocarcinoma; Dendritic cells; Immunotherapy; Cytotoxic T-cell responses; Tumor microenvironment; Combinatorial treatment modalities;

D O I：

10.1016/j.humimm.2008.07.006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Esophageal adenocarcinoma (EAC) is an extremely aggressive disease with an overall 5 years survival rate of less than 20%. Current treatments, such as surgery, or chemo- and radiotherapy have only little effect on survival. Attempts to combine these treatment modalities were only limited successful with marginal improvement of prognosis. Therefore, novel treatment strategies are urgently needed. In a previous study we demonstrated that dendritic cell (DC) immunotherapy may be an attractive and promising approach to treat EAC. Although potent immune responses can be raised by DC therapy, there are several concerns about the immunosuppressive microenvironment that characterizes these cancers, which may inhibit an effective immune response. Here a general overview is given of the current management of EAC and immunotherapies. More specific focus is on the EAC tumor microenvironment, and several potential combinatorial strategies that can be explored for improving treatment of EAC. (c) 2008 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

引用

页码：614 / 624

页数：11

共 118 条

[81] Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: Application to active immunotherapy [J].